Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 71 for:    lung cancer | First posted from 01/01/2019 to 02/01/2019

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03800134
Recruitment Status : Recruiting
First Posted : January 11, 2019
Last Update Posted : June 25, 2020
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of major pathological response.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: Durvalumab Other: Placebo Drug: Carboplatin/Paclitaxel Drug: Cisplatin/Gemcitabine Drug: Pemetrexed/Cisplatin Drug: Pemetrexed/Carboplatin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 800 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
Actual Study Start Date : December 6, 2018
Estimated Primary Completion Date : January 5, 2024
Estimated Study Completion Date : January 5, 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Durvalumab

Arm Intervention/treatment
Experimental: Arm 1: Durvalumab + platinum-based chemotherapy

Durvalumab ((MEDI4736) in concurrence with platinum-based chemotherapy.

All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on tumour histology and Investigator discretion:

  • carboplatin/paclitaxel
  • cisplatin/gemcitabine
  • pemetrexed/cisplatin
  • pemetrexed/carboplatin
Drug: Durvalumab
Durvalumab IV (intravenous infusion)
Other Name: MEDI4736

Drug: Carboplatin/Paclitaxel
Carboplatin/Paclitaxel, as per standard of care

Drug: Cisplatin/Gemcitabine
Cisplatin/Gemcitabine, as per standard of care

Drug: Pemetrexed/Cisplatin
Pemetrexed/Cisplatin, as per standard of care

Drug: Pemetrexed/Carboplatin
Pemetrexed/Carboplatin, as per standard of care

Placebo Comparator: Arm 2: Placebo + platinum-based chemotherapy

Placebo in concurrence with platinum-based chemotherapy.

All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on tumour histology and Investigator discretion:

  • carboplatin/paclitaxel
  • cisplatin/gemcitabine
  • pemetrexed/cisplatin
  • pemetrexed/carboplatin
Other: Placebo
Placebo IV (intravenous infusion)

Drug: Carboplatin/Paclitaxel
Carboplatin/Paclitaxel, as per standard of care

Drug: Cisplatin/Gemcitabine
Cisplatin/Gemcitabine, as per standard of care

Drug: Pemetrexed/Cisplatin
Pemetrexed/Cisplatin, as per standard of care

Drug: Pemetrexed/Carboplatin
Pemetrexed/Carboplatin, as per standard of care




Primary Outcome Measures :
  1. Major Pathological Response (mPR) [ Time Frame: From screening pathology to an average of 15 weeks after first dose. ]
  2. Event-free survival [ Time Frame: Up to 5 years after first patient enrolled. ]

Secondary Outcome Measures :
  1. Pathological complete response (pCR) [ Time Frame: From screening pathology to an average of 15 weeks after first dose. ]
  2. mPR in PD-L1-TC positive patients [ Time Frame: From screening pathology to an average of 15 weeks after first dose ]
  3. Event-free survival (EFS) [ Time Frame: From date of randomization to 5.5 years after randomization ]
  4. Disease-free survival (DFS) [ Time Frame: From date of randomization to 5.5 years after date of resection ]
  5. Overall Survival (OS) [ Time Frame: From date of randomization to 5.5 years after randomization ]
  6. To assess disease-related symptoms and HRQoL (EORTC QLQ-C30) in patients treated with durva + chemo prior to surgery followed by durva post-surgery compared with placebo + chemo prior to surgery followed by placebo post-surgery [ Time Frame: From date of screening to 6 months after last dose of IP ]
  7. To assess disease-related symptoms and HRQoL (EORTC QLQ-LC13) in patients treated with durva + chemo prior to surgery followed by durva post-surgery compared with placebo + chemo prior to surgery followed by placebo post-surgery [ Time Frame: From date of screening to 6 months after last dose of IP ]
  8. To assess the PK of durvalumab in blood (through concentration) [ Time Frame: From date of randomization to 2 months after resection ]
  9. Presence of ADA for durvalumab [ Time Frame: From date of randomization to 3 months after last dose of IP ]
  10. EFS and DFS in PD-L1 TC positive patients [ Time Frame: From date of resection up to 5.5 years after date of resection. ]

Other Outcome Measures:
  1. Number of participants with all adverse events as assessed by CTCAE v4.0 in durva + chemo prior to surgery followed by durva post-surgery compared with placebo + chemo prior to surgery followed by placebo post-surgery [ Time Frame: 64 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥18 years
  • Histologically or cytologically documented NSCLC with resectable (Stage IIA to select [ie, N2] Stage IIIB) disease
  • World Health Organization (WHO)/ECOG PS of 0 or 1 at enrollment
  • At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target Lesion (TL) at baseline
  • No prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines
  • Adequate organ and marrow function
  • Confirmation of a patients tumour PD-L1 status
  • Documented EGFR and ALK status

Exclusion Criteria:

  • History of allogeneic organ transplantation
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease, diverticulitis, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome)
  • History of another primary malignancy
  • History of active primary immunodeficiency
  • Active infection including tuberculosis hepatitis B, or human immunodeficiency virus
  • Deemed unresectable NSCLC by multidisciplinary evaluation
  • Patients who have pre-operative radiotherapy treatment as part of their care plan
  • Patients who have brain metastases or spinal cord compression
  • Stage IIIB N3 and Stages IIIC, IVA, and IVB NSCLC
  • Mixed small cell and NSCLC histology
  • Patients who are candidates to undergo only segmentectomies or wedge resections

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03800134


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com
Contact: AstraZeneca Cancer Study Locator 1-877-400-4656 astrazeneca@emergingmed.com

Locations
Hide Hide 210 study locations
Layout table for location information
United States, Arizona
Research Site Recruiting
Phoenix, Arizona, United States, 85054
United States, California
Research Site Recruiting
Duarte, California, United States, 91010
Research Site Recruiting
Orange, California, United States, 92868
Research Site Not yet recruiting
Rancho Mirage, California, United States, 92270
Research Site Withdrawn
San Diego, California, United States, 92123
United States, Florida
Research Site Recruiting
Boca Raton, Florida, United States, 33486-2305
Research Site Recruiting
Jacksonville, Florida, United States, 32256
Research Site Withdrawn
Tampa, Florida, United States, 33612
United States, Illinois
Research Site Recruiting
Chicago, Illinois, United States, 60612
United States, Kansas
Research Site Recruiting
Wichita, Kansas, United States, 67214
United States, Kentucky
Research Site Recruiting
Ashland, Kentucky, United States, 41101
Research Site Recruiting
Lexington, Kentucky, United States, 40513
United States, Maryland
Research Site Recruiting
Baltimore, Maryland, United States, 21204
Research Site Recruiting
Silver Spring, Maryland, United States, 20910
United States, Minnesota
Research Site Recruiting
Duluth, Minnesota, United States, 55805
Research Site Not yet recruiting
Minneapolis, Minnesota, United States, 55404
United States, New Jersey
Research Site Recruiting
Morristown, New Jersey, United States, 07962
United States, New York
Research Site Withdrawn
Bronx, New York, United States, 10469
Research Site Recruiting
New York, New York, United States, 10028
Research Site Not yet recruiting
New York, New York, United States, 10065
Research Site Recruiting
Port Jefferson Station, New York, United States, 11776
Research Site Not yet recruiting
Poughkeepsie, New York, United States, 12601
United States, North Carolina
Research Site Recruiting
Durham, North Carolina, United States, 27710
Research Site Withdrawn
Salisbury, North Carolina, United States, 28144
United States, Oregon
Research Site Recruiting
Bend, Oregon, United States, 97701
Research Site Recruiting
Medford, Oregon, United States, 97504
United States, Pennsylvania
Research Site Recruiting
Pittsburgh, Pennsylvania, United States, 15212
United States, South Carolina
Research Site Recruiting
Charleston, South Carolina, United States, 29424
United States, South Dakota
Research Site Withdrawn
Sioux Falls, South Dakota, United States, 57105
United States, Texas
Research Site Not yet recruiting
Austin, Texas, United States, 78745
Research Site Recruiting
Fort Worth, Texas, United States, 76104
Research Site Recruiting
Houston, Texas, United States, 77030
Research Site Recruiting
Houston, Texas, United States, 77090
United States, Virginia
Research Site Not yet recruiting
Fort Belvoir, Virginia, United States, 22060
Research Site Not yet recruiting
Newport News, Virginia, United States, 23601
United States, Washington
Research Site Withdrawn
Kennewick, Washington, United States, 99336
Research Site Recruiting
Kirkland, Washington, United States, 98034
Research Site Recruiting
Seattle, Washington, United States, 98109
Research Site Withdrawn
Seattle, Washington, United States, 98133
United States, West Virginia
Research Site Withdrawn
Morgantown, West Virginia, United States, 26506
Argentina
Research Site Recruiting
Buenos Aires, Argentina, C1118AAT
Research Site Recruiting
Caba, Argentina, C1012AAR
Research Site Recruiting
Caba, Argentina, C1280AEB
Research Site Withdrawn
Ciudad Autonoma De Buenos Aire, Argentina, C1125ABD
Research Site Withdrawn
Cordoba, Argentina, 5000
Research Site Withdrawn
Córdoba, Argentina, X5004BAL
Research Site Withdrawn
Florencio Varela, Argentina, 1888
Research Site Not yet recruiting
La Plata, Argentina, 1900
Research Site Not yet recruiting
Pergamino, Argentina, B2700CPM
Research Site Recruiting
Rosario, Argentina, S2000DEJ
Research Site Withdrawn
Rosario, Argentina, S2000DSV
Research Site Recruiting
San Salvador de Jujuy, Argentina, 4600
Research Site Withdrawn
Santa Rosa, Argentina, 6300
Research Site Recruiting
Viedma, Argentina, R8500ACE
Austria
Research Site Recruiting
Graz, Austria, 8036
Research Site Recruiting
Innsbruck, Austria, 6020
Research Site Recruiting
Rankweil, Austria, 6830
Research Site Not yet recruiting
Wien, Austria, 1090
Research Site Not yet recruiting
Wien, Austria, 1210
Belgium
Research Site Not yet recruiting
Gent, Belgium, 9000
Research Site Not yet recruiting
Liège, Belgium, 4000
Research Site Not yet recruiting
Mons, Belgium, 7000
Brazil
Research Site Not yet recruiting
Barretos, Brazil, 14784-400
Research Site Not yet recruiting
Campinas, Brazil, 13060-904
Research Site Not yet recruiting
Curitiba, Brazil, 81520-060
Research Site Not yet recruiting
Florianópolis, Brazil, 88034-000
Research Site Not yet recruiting
Natal, Brazil, 59075-740
Research Site Not yet recruiting
Porto Alegre, Brazil, 90610-000
Research Site Not yet recruiting
Sao Paulo, Brazil, 01246-000
Research Site Not yet recruiting
Sao Paulo, Brazil, 01323-903
Research Site Not yet recruiting
São José do Rio Preto, Brazil, 15090-000
Bulgaria
Research Site Not yet recruiting
Plovdiv, Bulgaria, 4004
Research Site Withdrawn
Plovdiv, Bulgaria, 4109
Research Site Recruiting
Sofia, Bulgaria, 1330
Research Site Not yet recruiting
Sofia, Bulgaria, 1618
Research Site Not yet recruiting
Varna, Bulgaria, 9010
Canada, Alberta
Research Site Not yet recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Canada, Ontario
Research Site Not yet recruiting
Kitchener, Ontario, Canada, N2G 1G3
Research Site Withdrawn
London, Ontario, Canada, N6A 4L6
Canada, Quebec
Research Site Suspended
Levis, Quebec, Canada, G6V 3Z1
Research Site Suspended
Montreal, Quebec, Canada, H1T 2M4
Research Site Suspended
Montreal, Quebec, Canada, H4J 1C5
Canada, Saskatchewan
Research Site Not yet recruiting
Saskatoon, Saskatchewan, Canada, S7N 4H4
Canada
Research Site Suspended
Quebec, Canada, G1V 4G5
Chile
Research Site Withdrawn
Santiago de Chile, Chile, 6770128
Research Site Recruiting
Santiago, Chile, 7500713
Research Site Recruiting
Santiago, Chile, 7520349
Research Site Not yet recruiting
Santiago, Chile, 7560171
Research Site Recruiting
Viña del Mar, Chile, 2540488
China
Research Site Not yet recruiting
Shanghai, China, 200433
France
Research Site Not yet recruiting
Lyon Cedex 08, France, 69373
Research Site Not yet recruiting
Toulon Armees, France, 83800
Research Site Not yet recruiting
Vantoux, France, 57070
Germany
Research Site Not yet recruiting
Göttingen, Germany, 37075
Research Site Not yet recruiting
Immenstadt im Allgäu, Germany, 87509
Research Site Not yet recruiting
Köln, Germany, 51109
Hungary
Research Site Recruiting
Budapest, Hungary, 1121
Research Site Recruiting
Győr, Hungary, 9024
Research Site Recruiting
Mátraháza, Hungary, H-3233
Research Site Recruiting
Székesfehérvár, Hungary, 8000
India
Research Site Recruiting
Ahmedabad, India, 380060
Research Site Withdrawn
Bangalore, India, 560068
Research Site Not yet recruiting
Chandigarh, India, 160012
Research Site Recruiting
Gurgaon, India, 122001
Research Site Recruiting
Kolkata, India, 700160
Research Site Not yet recruiting
Madurai, India, 625107
Research Site Recruiting
Maharashtra, India, 411013
Research Site Recruiting
Mumbai, India, 400053
Research Site Withdrawn
Nagpur, India, 440012
Research Site Not yet recruiting
Namakkal, India, 637001
Research Site Recruiting
Nasik, India, 422002
Research Site Recruiting
New Delhi, India, 110063
Research Site Recruiting
New Delhi, India, 110085
Research Site Not yet recruiting
Surat, India, 395009
Research Site Not yet recruiting
Thane, India, 401107
Research Site Recruiting
Vishakhapatnam, India, 530017
Italy
Research Site Not yet recruiting
Ancona, Italy, 60126
Research Site Not yet recruiting
Bari, Italy, 70124
Research Site Not yet recruiting
Bergamo, Italy, 24127
Research Site Not yet recruiting
Milano, Italy, 20132
Research Site Not yet recruiting
Monza, Italy, 20900
Research Site Not yet recruiting
Padova, Italy, 35128
Research Site Not yet recruiting
Roma, Italy, 00100
Research Site Not yet recruiting
Verona, Italy, 37126
Japan
Research Site Recruiting
Habikino-shi, Japan, 583-8588
Research Site Recruiting
Himeji-shi, Japan, 670-8520
Research Site Recruiting
Hiroshima-shi, Japan, 730-8518
Research Site Recruiting
Hiroshima-shi, Japan, 734-8551
Research Site Recruiting
Iwakuni-shi, Japan, 740-8510
Research Site Recruiting
Kitaadachi-gun, Japan, 362-0806
Research Site Recruiting
Kitakyushu-shi, Japan, 807-8555
Research Site Recruiting
Kurashiki shi, Japan, 701 0192
Research Site Recruiting
Nagoya-shi, Japan, 464-8681
Research Site Recruiting
Niigata-shi, Japan, 951-8566
Research Site Recruiting
Okayama-shi, Japan, 700-8558
Research Site Recruiting
Osakasayama-shi, Japan, 589-8511
Research Site Recruiting
Toyoake-shi, Japan, 470-1192
Research Site Recruiting
Wakayama-shi, Japan, 641-8510
Korea, Republic of
Research Site Recruiting
Busan, Korea, Republic of, 48108
Research Site Recruiting
Cheongju-si, Korea, Republic of, 28644
Research Site Withdrawn
Incheon, Korea, Republic of, 21565
Research Site Recruiting
Seongnam-si, Korea, Republic of, 13620
Research Site Recruiting
Seoul, Korea, Republic of, 05505
Research Site Recruiting
Seoul, Korea, Republic of, 06591
Research Site Recruiting
Suwon-si, Korea, Republic of, 16247
Research Site Recruiting
Suwon-si, Korea, Republic of, 16499
Mexico
Research Site Recruiting
Aguascalientes, Mexico, 20230
Research Site Recruiting
Guadalajara, Mexico, 44680
Research Site Recruiting
Monterrey, Mexico, 64000
Research Site Recruiting
México, Mexico, 1400
Research Site Recruiting
México, Mexico, 14050
Research Site Not yet recruiting
Pachuca de Soto, Mexico, 42090
Netherlands
Research Site Not yet recruiting
Arnhem, Netherlands, 6815 AD
Research Site Not yet recruiting
Nijmegen, Netherlands, 6525 GA
Peru
Research Site Not yet recruiting
Bellavista, Peru, CALLAO 2
Research Site Not yet recruiting
Chiclayo, Peru
Research Site Not yet recruiting
La Libertad, Peru, 13013
Research Site Not yet recruiting
Lima, Peru, LIMA 11
Research Site Not yet recruiting
Lima, Peru, LIMA 31
Research Site Not yet recruiting
Lima, Peru, Lima 32
Research Site Not yet recruiting
Lima, Peru, LIMA 34
Research Site Not yet recruiting
San Isidro, Peru, 27
Philippines
Research Site Suspended
Davao City, Philippines, 8000
Research Site Suspended
Iloilo City, Philippines, 5000
Research Site Suspended
Makati, Philippines, 1229
Research Site Suspended
Manila, Philippines, 1000
Research Site Suspended
Manila, Philippines, 1015
Research Site Suspended
Quezon City, Philippines, 1100
Romania
Research Site Not yet recruiting
Suceava, Romania, 720237
Russian Federation
Research Site Recruiting
Kazan, Russian Federation, 420029
Research Site Recruiting
Krasnoyarsk, Russian Federation, 660133
Research Site Suspended
Moscow, Russian Federation, 105229
Research Site Suspended
Moscow, Russian Federation, 115008
Research Site Withdrawn
Moscow, Russian Federation, 115478
Research Site Withdrawn
Novosibirsk, Russian Federation, 630108
Research Site Withdrawn
Obninsk, Russian Federation, 249036
Research Site Not yet recruiting
Obninsk, Russian Federation, 249036
Research Site Withdrawn
Omsk, Russian Federation, 644013
Research Site Recruiting
Rostov-on-Don, Russian Federation, 344037
Research Site Withdrawn
Saint-Petersburg, Russian Federation, 194291
Research Site Withdrawn
St. Petersburg, Russian Federation, 194291
Research Site Suspended
St. Petersburg, Russian Federation, 197022
Research Site Withdrawn
Syktyvkar, Russian Federation, 167904
Research Site Withdrawn
Tomsk, Russian Federation, 634009
Research Site Not yet recruiting
Tomsk, Russian Federation, 634063
Spain
Research Site Not yet recruiting
Málaga, Spain, 29010
Research Site Not yet recruiting
Oviedo, Spain, 33011
Research Site Not yet recruiting
Pamplona, Spain, 31008
Research Site Not yet recruiting
San Sebastian, Spain, 20014
Research Site Not yet recruiting
Santiago De Compostela(A Coru, Spain, 15706
Taiwan
Research Site Not yet recruiting
Changhua, Taiwan, 500
Research Site Recruiting
Taichung City, Taiwan, 402
Research Site Recruiting
Taichung, Taiwan, 40705
Research Site Recruiting
Tainan City, Taiwan, 70403
Research Site Not yet recruiting
Tainan City, Taiwan, 73657
Research Site Recruiting
Taipei City, Taiwan, 110
Research Site Recruiting
Taipei, Taiwan, 10002
Research Site Recruiting
Taipei, Taiwan, 235
Research Site Not yet recruiting
Tao-Yuan, Taiwan, 333
Thailand
Research Site Recruiting
Bangkok, Thailand, 10300
Research Site Recruiting
Bangkok, Thailand, 10330
Research Site Recruiting
Chiang Mai, Thailand, 50200
Research Site Recruiting
Khon Kaen, Thailand, 40002
Research Site Recruiting
Lampang, Thailand, 52000
Research Site Recruiting
Muang, Thailand, 57000
Vietnam
Research Site Recruiting
Hanoi, Vietnam, 100000
Research Site Recruiting
Ho Chi Minh, Vietnam, 10000
Research Site Recruiting
Ho Chi Minh, Vietnam, 700000
Research Site Recruiting
Ho Chi Minh, Vietnam, 70000
Research Site Not yet recruiting
Ho Chi Minh, Vietnam, 70000
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: John Heymach, MD UT MD Anderson Cancer Institute
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT03800134    
Other Study ID Numbers: D9106C00001
First Posted: January 11, 2019    Key Record Dates
Last Update Posted: June 25, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
Resectable Non-small Cell Lung Cancer, NSCLC, Carcinoma, Non-small Cell Lung Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Bronchial Neoplasms
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Gemcitabine
Paclitaxel
Cisplatin
Carboplatin
Pemetrexed
Durvalumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs